MIT Alumni Taris Biomedical Nabs $15M VC Investment to Develop Drug-Delivery Tech
June 30, 2009
MIT Alumni Taris Biomedical Nabs $15M VC Investment to Develop Drug-Delivery Tech
Taris is the latest MIT spinout to attract significant VC cash after receiving early-stage proof-of-concept funding from the school's Deshpande Center, further highlighting the center's ability to speed commercialization of MIT biomedical research.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Max Planck, Alnylam Sue Whitehead, MIT, UMass for Breach of Contract in RNAi Patent Filings
July 1, 2009 / - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology
February 28, 2013 / Gene Silencing News - Study Uncovers Coordinated Transcription for Protein-Coding and RNAs
February 5, 2013 / GenomeWeb Daily News - Paper Outlines Proteomic Method Based on Engineered Peroxidase Enzyme
February 1, 2013 / GenomeWeb Daily News